Lava Therapeutics B.V. Competitors

The Joint (NASDAQ:JYNT) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

82.1% of The Joint shares are held by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are held by institutional investors. 4.6% of The Joint shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares The Joint and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

The Joint has higher revenue and earnings than Lava Therapeutics B.V..

Analyst Recommendations

This is a breakdown of recent ratings for The Joint and Lava Therapeutics B.V., as reported by MarketBeat.

The Joint presently has a consensus target price of $55.40, indicating a potential downside of 29.00%. Lava Therapeutics B.V. has a consensus target price of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s stronger consensus rating and higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than The Joint.

Profitability

This table compares The Joint and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Summary

The Joint beats Lava Therapeutics B.V. on 7 of the 9 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

36.3% of Lava Therapeutics B.V. shares are held by institutional investors. 13.0% of Coherus BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Coherus BioSciences and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Coherus BioSciences has higher revenue and earnings than Lava Therapeutics B.V..

Analyst Recommendations

This is a breakdown of recent ratings for Coherus BioSciences and Lava Therapeutics B.V., as reported by MarketBeat.

Coherus BioSciences presently has a consensus target price of $24.8333, indicating a potential upside of 69.63%. Lava Therapeutics B.V. has a consensus target price of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s stronger consensus rating and higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than Coherus BioSciences.

Profitability

This table compares Coherus BioSciences and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Summary

Lava Therapeutics B.V. beats Coherus BioSciences on 6 of the 9 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Valuation and Earnings

This table compares Atrion and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Atrion has higher revenue and earnings than Lava Therapeutics B.V..

Insider and Institutional Ownership

65.6% of Atrion shares are held by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are held by institutional investors. 22.0% of Atrion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Atrion and Lava Therapeutics B.V., as reported by MarketBeat.

Lava Therapeutics B.V. has a consensus target price of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than Atrion.

Profitability

This table compares Atrion and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Summary

Atrion beats Lava Therapeutics B.V. on 6 of the 8 factors compared between the two stocks.

NextGen Healthcare (NASDAQ:NXGN) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Valuation & Earnings

This table compares NextGen Healthcare and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

NextGen Healthcare has higher revenue and earnings than Lava Therapeutics B.V..

Insider & Institutional Ownership

74.1% of NextGen Healthcare shares are owned by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are owned by institutional investors. 18.7% of NextGen Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for NextGen Healthcare and Lava Therapeutics B.V., as reported by MarketBeat.com.

NextGen Healthcare currently has a consensus price target of $21.00, indicating a potential upside of 27.20%. Lava Therapeutics B.V. has a consensus price target of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s stronger consensus rating and higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than NextGen Healthcare.

Profitability

This table compares NextGen Healthcare and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Summary

NextGen Healthcare beats Lava Therapeutics B.V. on 7 of the 9 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Valuation & Earnings

This table compares Cullinan Oncology and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Insider & Institutional Ownership

72.0% of Cullinan Oncology shares are owned by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are owned by institutional investors. 21.8% of Cullinan Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Cullinan Oncology and Lava Therapeutics B.V., as reported by MarketBeat.com.

Cullinan Oncology currently has a consensus price target of $51.75, indicating a potential upside of 103.90%. Lava Therapeutics B.V. has a consensus price target of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than Cullinan Oncology.

Profitability

This table compares Cullinan Oncology and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Summary

Cullinan Oncology beats Lava Therapeutics B.V. on 3 of the 4 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Valuation & Earnings

This table compares Vaxcyte and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Insider & Institutional Ownership

85.7% of Vaxcyte shares are owned by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are owned by institutional investors. 21.7% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Vaxcyte and Lava Therapeutics B.V., as reported by MarketBeat.com.

Vaxcyte currently has a consensus price target of $48.00, indicating a potential upside of 123.46%. Lava Therapeutics B.V. has a consensus price target of $23.6667, indicating a potential upside of 114.57%. Given Vaxcyte's higher possible upside, equities research analysts plainly believe Vaxcyte is more favorable than Lava Therapeutics B.V..

Profitability

This table compares Vaxcyte and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Summary

Vaxcyte beats Lava Therapeutics B.V. on 4 of the 6 factors compared between the two stocks.